Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies

NCT05828589 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT05828589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05828589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Terminated
Start date
June 20, 2023
Completion date
June 8, 2026
Enrollment
51 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

refractory chronic lymphocytic leukemia, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory marginal zone lymphoma, refractory non-hodgkin lymphoma, refractory small lymphocytic lymphoma, relapse diffuse large b cell lymphoma, relapsed chronic lymphocytic leukemia, relapsed follicular lymphoma, relapsed marginal zone lymphoma, relapsed non-hodgkin lymphoma, relapsed small lymphocytic lymphoma, richter transformation, transformed non-hodgkin lymphoma